This Popular Biotech Could Be in Trouble
The following video is part of our "Motley Fool Conversations" series, in which health-care editor/analyst David Williamson and industrials editor/analyst Brendan Byrnes discuss topics across the investing world.
In this video, David and Brendan discuss Dendreon's fourth-quarter earnings and first-quarter guidance. Share price volatility around earnings along with slowing sequential sales and new competitors on the horizon have investors nervous. Should they be? Watch and find out.
Health-care investors are always looking for the next big breakthrough. Motley Fool co-founder David Gardner recently identified a small-cap health-care company that he believes is poised for monster returns. To uncover this top pick today, enjoy the special free report: "Discover the Next Rule-Breaking Multibagger." Don't miss out on this limited-time offer and your opportunity to discover this game-changing company before the market does. Click here to access your report -- it's totally free.
At the time this article was published Brendan Byrnes has no positions in the stocks mentioned above. David Williamson owns shares of Dendreon. The Motley Fool owns shares of Dendreon, Exelixis, and GlaxoSmithKline.Motley Fool newsletter services recommendExelixis and GlaxoSmithKline. Try any of our Foolish newsletter servicesfree for 30 days. We Fools may not all hold the same opinions, but we all believe thatconsidering a diverse range of insightsmakes us better investors. The Motley Fool has adisclosure policy.
Copyright © 1995 - 2012 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.